Cite
HARVARD Citation
Rösner, T. et al. (n.d.). An IgG3 switch variant of rituximab mediates enhanced complement‐dependent cytotoxicity against tumour cells with low CD20 expression levels. British journal of haematology. pp. 282-286. [Online].